← Leaderboards
Charles P Emerson
University Of Pennsylvania
$35,198,488
Attributed
$38,205,175
Total exposure
25
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$62,931,406 · 27
By mechanism
U54$26,981,815 · 10
P50$16,532,607 · 7
R37$7,222,333 · 1
R01$6,003,070 · 2
R24$3,311,875 · 1
R21$1,175,000 · 3
Top collaborators
- Michael Allen Brehm4 shared
- Dale L Greiner4 shared
- Jeremy Luban4 shared
- Leonard D. Shultz4 shared
- Henry Paulus2 shared
- Scot A Wolfe2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Alejandro D. Arroyo Pacheco$105,980
- Krista H Vandenborne$30,884,872
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMuscleFacioscapulohumeral Muscular DystrophyGenesMuscular DystrophiesBaseMuscle CellsResearch PersonnelBiological MarkersResourcesCollaborationsFamilyMolecularMouse ModelNovel TherapeuticsGeneticTranscription FactorAffectBiopsyRepositoryGene ExpressionCommunitiesBioinformaticsMeetings
Grant awards (134)
Novel therapeutics for FSHD$746,947
P50 · FY2023 · HD · contact PI
Novel Therapeutics for FSHD$1,541,442
P50 · FY2022 · HD · contact PI
Immunogenicity of Human Stem Cell-Derived Beta Cells and Muscle Cells in Humanized Mice$823,750
R24 · FY2022 · OD
Novel Therapeutics for FSHD - Resources Core - Core C$398,391
P50 · FY2022 · HD · contact PI
FSHD Genetic Modifiers$388,796
P50 · FY2022 · HD · contact PI
FSHD Drug Discovery$290,472
P50 · FY2022 · HD · contact PI
FSHD Pre-clinical Development$232,279
P50 · FY2022 · HD · contact PI
Training Core [Parent Title: NOVEL THERAPEUTICS FOR FSHD]$126,560
P50 · FY2022 · HD · contact PI
Administrative Core - Novel Therapeutics for FSHD$104,944
P50 · FY2022 · HD · contact PI
Novel Therapeutics for FSHD$1,541,442
P50 · FY2021 · HD · contact PI
Immunogenicity of Human Stem Cell-Derived Beta Cells and Muscle Cells in Humanized Mice$823,750
R24 · FY2021 · OD
Novel Therapeutics for FSHD - Resources Core - Core C$395,561
P50 · FY2021 · HD · contact PI
FSHD Genetic Modifiers$386,158
P50 · FY2021 · HD · contact PI
FSHD Drug Discovery$289,801
P50 · FY2021 · HD · contact PI
FSHD Pre-clinical Development$232,772
P50 · FY2021 · HD · contact PI
Training Core [Parent Title: NOVEL THERAPEUTICS FOR FSHD]$129,167
P50 · FY2021 · HD · contact PI
Administrative Core - Novel Therapeutics for FSHD$107,983
P50 · FY2021 · HD · contact PI
Novel Therapeutics for FSHD$1,541,442
P50 · FY2020 · HD · contact PI
Immunogenicity of Human Stem Cell-Derived Beta Cells and Muscle Cells in Humanized Mice$823,750
R24 · FY2020 · OD
Novel Therapeutics for FSHD - Resources Core - Core C$395,561
P50 · FY2020 · HD · contact PI
FSHD Genetic Modifiers$386,158
P50 · FY2020 · HD · contact PI
FSHD Drug Discovery$289,801
P50 · FY2020 · HD · contact PI
FSHD Pre-clinical Development$232,772
P50 · FY2020 · HD · contact PI
Training Core [Parent Title: NOVEL THERAPEUTICS FOR FSHD]$129,167
P50 · FY2020 · HD · contact PI
Administrative Core - Novel Therapeutics for FSHD$107,983
P50 · FY2020 · HD · contact PI
Novel Therapeutics for FSHD$1,552,437
P50 · FY2019 · HD · contact PI
Immunogenicity of Human Stem Cell-Derived Beta Cells and Muscle Cells in Humanized Mice$840,625
R24 · FY2019 · OD
Novel Therapeutics for FSHD - Resources Core - Core C$397,394
P50 · FY2019 · HD · contact PI
FSHD Genetic Modifiers$387,991
P50 · FY2019 · HD · contact PI
FSHD Drug Discovery$291,634
P50 · FY2019 · HD · contact PI
FSHD Pre-clinical Development$234,604
P50 · FY2019 · HD · contact PI
A comprehensive gene repair therapy for FKRP neuromuscular diseases$209,375
R21 · FY2019 · NS · contact PI
An innate immunity model of FSHD muscle pathology$209,375
R21 · FY2019 · NS · contact PI
Training Core [Parent Title: NOVEL THERAPEUTICS FOR FSHD]$130,999
P50 · FY2019 · HD · contact PI
Administrative Core - Novel Therapeutics for FSHD$109,815
P50 · FY2019 · HD · contact PI
Training Core [Parent Title: NOVEL THERAPEUTICS FOR FSHD]$1,716,067
P50 · FY2018 · HD · contact PI
Novel Therapeutics for FSHD - Resources Core - Core C$488,071
P50 · FY2018 · HD · contact PI
FSHD Genetic Modifiers$401,070
P50 · FY2018 · HD · contact PI
FSHD Drug Discovery$306,367
P50 · FY2018 · HD · contact PI
FSHD Pre-clinical Development$252,002
P50 · FY2018 · HD · contact PI
An innate immunity model of FSHD muscle pathology$251,250
R21 · FY2018 · NS · contact PI
A comprehensive gene repair therapy for FKRP neuromuscular diseases$251,250
R21 · FY2018 · NS · contact PI
Training Core [Parent Title: NOVEL THERAPEUTICS FOR FSHD]$149,349
P50 · FY2018 · HD · contact PI
Administrative Core - Novel Therapeutics for FSHD$119,208
P50 · FY2018 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,387,935
U54 · FY2017 · HD · contact PI
Genetic Modifiers of FSHD$416,329
U54 · FY2017 · HD · contact PI
Cell Core$335,862
U54 · FY2017 · HD · contact PI
Animal Models of FSHD for Therapy$321,398
U54 · FY2017 · HD · contact PI
FSHD Disease Biomarkers$270,593
U54 · FY2017 · HD · contact PI
Education and Training Core$148,510
U54 · FY2017 · HD · contact PI
Administrative Core$59,334
U54 · FY2017 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,376,163
U54 · FY2016 · HD · contact PI
Cell Core$335,862
U54 · FY2016 · HD · contact PI
Animal Models of FSHD for Therapy$321,399
U54 · FY2016 · HD · contact PI
FSHD Disease Biomarkers$270,594
U54 · FY2016 · HD · contact PI
Genetic Modifiers of FSHD$252,238
U54 · FY2016 · HD · contact PI
Education and Training Core$148,509
U54 · FY2016 · HD · contact PI
Administrative Core$47,561
U54 · FY2016 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,392,508
U54 · FY2015 · HD · contact PI
Cell Core$335,862
U54 · FY2015 · HD · contact PI
Animal Models of FSHD for Therapy$321,101
U54 · FY2015 · HD · contact PI
FSHD Disease Biomarkers$270,482
U54 · FY2015 · HD · contact PI
Genetic Modifiers of FSHD$252,146
U54 · FY2015 · HD · contact PI
Education and Training Core$148,510
U54 · FY2015 · HD · contact PI
Administrative Core$64,407
U54 · FY2015 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,363,623
U54 · FY2014 · HD · contact PI
Control of Muscle Protein Synthesis During Myogenesis$561,459
R01 · FY2014 · HD · contact PI
Cell Core$376,268
U54 · FY2014 · HD · contact PI
Animal Models of FSHD for Therapy$287,052
U54 · FY2014 · HD · contact PI
FSHD Disease Biomarkers$263,497
U54 · FY2014 · HD · contact PI
Genetic Modifiers of FSHD$245,290
U54 · FY2014 · HD · contact PI
Education and Training Core$147,209
U54 · FY2014 · HD · contact PI
Administrative Core$44,307
U54 · FY2014 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,500,000
U54 · FY2013 · HD · contact PI
Control of Muscle Protein Synthesis During Myogenesis$545,036
R01 · FY2013 · HD · contact PI
Cell Core$398,104
U54 · FY2013 · HD · contact PI
Animal Models of FSHD for Therapy$308,351
U54 · FY2013 · HD · contact PI
FSHD Disease Biomarkers$285,541
U54 · FY2013 · HD · contact PI
Genetic Modifiers of FSHD$284,764
U54 · FY2013 · HD · contact PI
Education and Training Core$159,272
U54 · FY2013 · HD · contact PI
Administrative Core$63,968
U54 · FY2013 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,086,205
U54 · FY2012 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$651,079
U54 · FY2012 · HD · contact PI
Control of Muscle Protein Synthesis During Myogenesis$585,186
R01 · FY2012 · HD · contact PI
Cell Core$343,676
U54 · FY2012 · HD · contact PI
Myogenesis Studies for FSHD Biomarkers$283,400
U54 · FY2012 · HD · contact PI
Administrative Core$104,117
U54 · FY2012 · HD · contact PI
Control of Muscle Protein Synthesis During Myogenesis$83,000
R01 · FY2012 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,766,112
U54 · FY2011 · HD · contact PI
Control of Muscle Protein Synthesis During Myogenesis$683,484
R01 · FY2011 · HD · contact PI
Cell Core$182,391
U54 · FY2011 · HD · contact PI
Myogenesis Studies for FSHD Biomarkers$143,787
U54 · FY2011 · HD · contact PI
Administrative Core$28,058
U54 · FY2011 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,731,891
U54 · FY2010 · HD · contact PI
Control of Muscle Protein Synthesis During Myogenesis$688,079
R01 · FY2010 · HD · contact PI
Cell Core$478,612
U54 · FY2010 · HD · contact PI
Myogenesis Studies for FSHD Biomarkers$322,876
U54 · FY2010 · HD · contact PI
Administrative Core$77,299
U54 · FY2010 · HD · contact PI
Identification of inhibitors of hedgehog autoprocessing$50,750
R21 · FY2010 · NS
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$11,774
R37 · FY2010 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,744,087
U54 · FY2009 · HD · contact PI
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$861,077
R37 · FY2009 · HD · contact PI
Cell Core$474,004
U54 · FY2009 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$342,766
U54 · FY2009 · HD · contact PI
Myogenesis Studies for FSHD Biomarkers$326,288
U54 · FY2009 · HD · contact PI
Identification of inhibitors of hedgehog autoprocessing$203,000
R21 · FY2009 · NS
Administrative Core$79,176
U54 · FY2009 · HD · contact PI
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$11,774
R37 · FY2009 · HD · contact PI
Biomarkers for Therapy of FSHD (U54)$1,744,085
U54 · FY2008 · HD · contact PI
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$803,052
R37 · FY2008 · HD · contact PI
Cell Core$466,499
U54 · FY2008 · HD · contact PI
Myogenesis Studies for FSHD Biomarkers$322,994
U54 · FY2008 · HD · contact PI
Administrative Core$77,864
U54 · FY2008 · HD · contact PI
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$795,571
R37 · FY2007 · HD · contact PI
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$795,469
R37 · FY2006 · HD · contact PI
Sonic Hedgehog Target Genes in Development and Cancer$623,965
R01 · FY2006 · CA · contact PI
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$850,285
R37 · FY2005 · HD
Sonic Hedgehog Target Genes in Development and Cancer$631,097
R01 · FY2005 · CA
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$737,884
R37 · FY2004 · HD
Sonic Hedgehog Target Genes in Development and Cancer$629,683
R01 · FY2004 · CA
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$598,098
R37 · FY2003 · HD
Sonic Hedgehog Target Genes in Development and Cancer$473,837
R01 · FY2003 · CA
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$118,461
R37 · FY2003 · HD
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$551,206
R37 · FY2002 · HD
Sonic Hedgehog Target Genes in Development and Cancer$498,244
R01 · FY2002 · CA
TRAINING PROGRAM IN DEVELOPMENTAL BIOLOGY$422,866
T32 · FY2002 · HD
Integrated Robotics for Microarray Assembly (IRMA)$391,604
S10 · FY2002 · RR
FUNCTION OF MYOSIN ISOFORMS$0
P01 · FY2002 · HL
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$535,151
R37 · FY2001 · HD
TRAINING PROGRAM IN DEVELOPMENTAL BIOLOGY$335,496
T32 · FY2001 · HD
FUNCTION OF MYOSIN ISOFORMS$0
P01 · FY2001 · HL
CONTROL OF MUSCLE PROTEIN SYNTHESIS DURING MYOGENESIS$552,531
R37 · FY2000 · HD
FUNCTION OF MYOSIN ISOFORMS$288,917
P01 · FY2000 · HL
TRAINING PROGRAM IN DEVELOPMENTAL BIOLOGY$265,823
T32 · FY2000 · HD